{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:49:35Z","timestamp":1792900175851,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.atherosclerosis.2025.120485","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T15:52:15Z","timestamp":1755100335000},"page":"120485","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Associations of ANGPTL proteins and complexes with progression of coronary artery calcification and coronary events"],"prefix":"10.1016","volume":"409","author":[{"given":"G\u00fcnther","family":"Silbernagel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halle","family":"Higbie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Meininger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deven","family":"Lemen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan Q.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene Y.","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue-Wei","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polina","family":"Korovianskaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans J.","family":"Trampisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Scharnagl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried","family":"M\u00e4rz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Stang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raimund","family":"Erbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0923-0542","authenticated-orcid":false,"given":"Robert J.","family":"Konrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00f6rge","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2025.120485_bib1","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2025.120485_bib2","doi-asserted-by":"crossref","DOI":"10.1172\/JCI148559","article-title":"Addressing dyslipidemic risk beyond LDL-cholesterol","volume":"132","author":"Tall","year":"2022","journal-title":"J Clin Investig"},{"key":"10.1016\/j.atherosclerosis.2025.120485_bib3","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.tem.2020.11.005","article-title":"Lipoprotein lipase and its regulators: an unfolding story","volume":"32","author":"Wu","year":"2021","journal-title":"Trends Endocrinol Metabol"},{"key":"10.1016\/j.atherosclerosis.2025.120485_bib4","doi-asserted-by":"crossref","DOI":"10.1002\/adbi.202200093","article-title":"The regulation of triacylglycerol metabolism and lipoprotein lipase activity","author":"Wen","year":"2022","journal-title":"Adv Biol"},{"key":"10.1016\/j.atherosclerosis.2025.120485_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.119235","article-title":"Angiopoietin-like protein inhibitors: promising agents for the treatment of familial hypercholesterolemia and atherogenic dyslipidemia","volume":"405","author":"Vahdat-Lasemi","year":"2025","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2025.120485_bib6","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2214081120","article-title":"Angiopoietin-like protein 4\/8 complex-mediated plasmin generation leads to cleavage of the complex and restoration of LPL activity","volume":"120","author":"Zhen","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.atherosclerosis.2025.120485_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2023.100441","article-title":"Decoding the role of angiopoietin-like protein 4\/8 complex-mediated plasmin generation in the regulation of LPL activity","volume":"64","author":"Chen","year":"2023","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2025.120485_bib8","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1161\/CIRCULATIONAHA.124.069272","article-title":"Associations of circulating ANGPTL3, C-terminal domain-containing ANGPTL4, and ANGPTL3\/8 and ANGPTL4\/8 complexes with LPL activity, diabetes, inflammation, and cardiovascular mortality","volume":"151","author":"Silbernagel","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2025.120485_bib9","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1194\/jlr.RA120000781","article-title":"Angiopoietin-like protein 8 differentially regulates ANGPTL3 and ANGPTL4 during postprandial partitioning of fatty acids","volume":"61","author":"Chen","year":"2020","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2025.120485_bib10","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1612790","article-title":"Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease","volume":"377","author":"Dewey","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2025.120485_bib11","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJMoa1507652","article-title":"Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease","volume":"374","author":"Stitziel","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2025.120485_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1009501","article-title":"FinnGen. ANGPTL8 protein-truncating variant associated with lower serum triglycerides and risk of coronary disease","volume":"17","author":"Helkkula","year":"2021","journal-title":"PLoS Genet"},{"key":"10.1016\/j.atherosclerosis.2025.120485_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.119110","article-title":"Identifying novel drug targets for calcific aortic valve disease through Mendelian randomization","volume":"402","author":"Xu","year":"2025","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2025.120485_bib14","doi-asserted-by":"crossref","DOI":"10.1093\/ehjopen\/oeae035","article-title":"Drug-target Mendelian randomization analysis supports lowering plasma ANGPTL3, ANGPTL4, and APOC3 levels as strategies for reducing cardiovascular disease risk","volume":"4","author":"Landfors","year":"2024","journal-title":"Eur Heart J Open"},{"key":"10.1016\/j.atherosclerosis.2025.120485_bib15","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1093\/eurheartj\/ehaa972","article-title":"Metabolic profiling of angiopoietin-like protein 3 and 4 inhibition: a drug-target Mendelian randomization analysis","volume":"42","author":"Wang","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2025.120485_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2022.100313","article-title":"Genetic mimicry analysis reveals the specific lipases targeted by the ANGPTL3-ANGPTL8 complex and ANGPTL4","volume":"64","author":"Landfors","year":"2023","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2025.120485_bib17","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/eurheartj\/ehad845","article-title":"Genetic inhibition of angiopoietin-like protein-3, lipids, and cardiometabolic risk","volume":"45","author":"Gobeil","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2025.120485_bib18","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1194\/jlr.RA120000888","article-title":"Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance","volume":"61","author":"Adam","year":"2020","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2025.120485_bib19","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1002926","article-title":"Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia","volume":"363","author":"Musunuru","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2025.120485_bib20","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1067\/mhj.2002.123579","volume":"144","author":"Schmermund","year":"2002","journal-title":"Am Heart J"},{"key":"10.1016\/j.atherosclerosis.2025.120485_bib21","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10654-005-5529-z","article-title":"Baseline recruitment and analyses of nonresponse of the Heinz Nixdorf Recall Study: identifiability of phone numbers as the major determinant of response","volume":"20","author":"Stang","year":"2005","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.atherosclerosis.2025.120485_bib22","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1093\/eurheartj\/ehu288","article-title":"Progression of coronary artery calcification seems to be inevitable, but predictable \u2013 results of the Heinz Nixdorf Recall (HNR) study","volume":"35","author":"Erbel","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2025.120485_bib23","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.atherosclerosis.2005.06.003","article-title":"Population-based assessment of subclinical coronary atherosclerosis using electron-beam computed tomography","volume":"185","author":"Schmermund","year":"2006","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2025.120485_bib24","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0735-1097(90)90282-T","article-title":"Quantification of coronary artery calcium using ultrafast computed tomography","volume":"15","author":"Agatston","year":"1990","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120485_bib25","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jacc.2010.06.030","article-title":"Heinz Nixdorf Recall Study Investigative Group. Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: the Heinz Nixdorf Recall study","volume":"56","author":"Erbel","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120485_bib26","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1161\/CIRCULATIONAHA.116.027034","article-title":"Value of progression of coronary artery calcification for risk prediction of coronary and cardiovascular events: result of the HNR study (Heinz Nixdorf recall)","volume":"137","author":"Lehmann","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2025.120485_bib27","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jdiacomp.2016.08.011","article-title":"Progression of coronary artery calcification is stronger in poorly than in well controlled diabetes: results from the Heinz Nixdorf Recall Study","volume":"31","author":"Kowall","year":"2017","journal-title":"J Diabetes Complicat"},{"key":"10.1016\/j.atherosclerosis.2025.120485_bib28","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0140-6736(23)00215-5","article-title":"PROMINENT, REDUCE-IT, and STRENGTH Investigators. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomized trials","volume":"401","author":"Ridker","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2025.120485_bib29","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1161\/CIRCULATIONAHA.123.066213","article-title":"CLEAR outcomes investigators. Inflammation and cholesterol as predictors of cardiovascular events among 13970 contemporary high-risk patients with statin intolerance","volume":"149","author":"Ridker","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2025.120485_bib30","article-title":"Association between low density lipoprotein and all cause and cause specific mortality in Denmark: prospective cohort study","volume":"371","author":"Johannesen","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.atherosclerosis.2025.120485_bib31","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1161\/ATVBAHA.124.321308","article-title":"Circulating ANGPTL3\/8 concentrations are associated with an atherogenic lipoprotein profile and increased CHD risk in Swedish population-based studies","volume":"45","author":"Leander","year":"2025","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2025.120485_bib32","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"ELIPSE HoFH investigators. Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2025.120485_bib33","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jacc.2021.04.091","article-title":"Inhibition of angiopoietin-like protein 3 with evinacumab in subjects with high and severe hypertriglyceridemia","volume":"78","author":"Ahmad","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120485_bib34","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jacc.2020.05.070","article-title":"Targeting RNA with antisense oligonucleotides and small interfering RNA: JACC state-of-the-art review","volume":"76","author":"Katzmann","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120485_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2022.100198","article-title":"An anti-ANGPTL3\/8 antibody decreases circulating triglycerides by binding to a LPL-inhibitory leucine zipper-like motif","volume":"63","author":"Balasubramaniam","year":"2022","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2025.120485_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2021.100068","article-title":"ApoA5 lowers triglyceride levels via suppression of ANGPTL3\/8-mediated LPL inhibition","volume":"62","author":"Chen","year":"2021","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2025.120485_bib37","article-title":"Carboxyl-terminal sequences in APOA5 are important for suppressing ANGPTL3\/8 activity","volume":"121","author":"Chen","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.atherosclerosis.2025.120485_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2024.100578","article-title":"APOA5 deficiency causes hypertriglyceridemia by reducing amounts of lipoprotein lipase in capillaries","volume":"65","author":"Yang","year":"2024","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2025.120485_bib39","doi-asserted-by":"crossref","DOI":"10.1172\/JCI172600","article-title":"Hypertriglyceridemia in Apoa5-\/- mice results from reduced amounts of lipoprotein lipase in the capillary lumen","volume":"133","author":"Yang","year":"2023","journal-title":"J Clin Investig"},{"key":"10.1016\/j.atherosclerosis.2025.120485_bib40","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature13917","article-title":"Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction","volume":"518","author":"Do","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.atherosclerosis.2025.120485_bib41","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1016\/S0140-6736(25)00825-6","article-title":"Safety and efficacy of a novel ANGPTL4 inhibitory antibody for lipid lowering: results from phase 1 and phase 1b\/2a clinical studies","volume":"405","author":"Cummings","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2025.120485_bib42","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2014-000034","article-title":"Inflammation increases plasma angiopoietin-like protein 4 in patients with the metabolic syndrome and type 2 diabetes","volume":"2","author":"Tjeerdema","year":"2014","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.atherosclerosis.2025.120485_bib43","article-title":"Angiopoietin-like protein 4 (ANGPTL4) is an inhibitor of endothelial lipase (EL) while the ANGPTL4\/8 complex has reduced EL-inhibitory activity","volume":"30","author":"Chen","year":"2021","journal-title":"Heliyon"},{"key":"10.1016\/j.atherosclerosis.2025.120485_bib44","doi-asserted-by":"crossref","first-page":"28488","DOI":"10.1074\/jbc.M004029200","article-title":"Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene","volume":"275","author":"Kersten","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2025.120485_bib45","doi-asserted-by":"crossref","first-page":"34411","DOI":"10.1074\/jbc.M403058200","article-title":"The direct peroxisome proliferator-activated receptor target fasting-induced adipose factor (FIAF\/PGAR\/ANGPTL4) is present in blood plasma as a truncated protein that is increased by fenofibrate treatment","volume":"279","author":"Mandard","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2025.120485_bib46","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1161\/ATVBAHA.108.182147","article-title":"Caloric restriction and exercise increase plasma ANGPTL4 levels in humans via elevated free fatty acids","volume":"29","author":"Kersten","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2025.120485_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101033","article-title":"Fasting induces ANGPTL4 and reduces LPL activity in human adipose tissue","volume":"40","author":"Ruppert","year":"2020","journal-title":"Mol Metab"},{"key":"10.1016\/j.atherosclerosis.2025.120485_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2021.100150","article-title":"Role and mechanism of the action of angiopoietin-like protein ANGPTL4 in plasma lipid metabolism","volume":"62","author":"Kersten","year":"2021","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2025.120485_bib49","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nrendo.2017.119","article-title":"Angiopoietin-like 3 in lipoprotein metabolism","volume":"13","author":"Kersten","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.atherosclerosis.2025.120485_bib50","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.jacc.2010.10.043","article-title":"Quantification of coronary atherosclerosis and inflammation to predict coronary events and all-cause mortality","volume":"57","author":"M\u00f6hlenkamp","year":"2011","journal-title":"J Am Coll Cardiol"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915025013838?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915025013838?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T11:01:42Z","timestamp":1763204502000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915025013838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":50,"alternative-id":["S0021915025013838"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.120485","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Associations of ANGPTL proteins and complexes with progression of coronary artery calcification and coronary events","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.120485","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"120485"}}